European Neuropsychopharmacology, 10 February 2020
—
Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychot…
Inflammopharmacology, June 2019
—
BACKGROUND: The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis. METHODS: This was a single site, comparative, double-blind placebo controlled study i…
Life Sciences, 15 November 2018
—
Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and others have been suggested. It seems that the endocannabinoid system is also inv…
Drug and Alcohol Dependence, June 2018
—
BACKGROUND: We sought to describe the correlates of marijuana use during and after pregnancy, and to examine the independent relationship between prenatal marijuana use and infant outcomes. STUDY DESIGN: We used state-specific data from the Pregnancy Risk Assessment Monitoring…
Alcohol & Drug Abuse Institute, University of Washington, June 2017
—
THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…
BMJ, 23 November 2002
—
The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. This study could not establish whether adolescent cannabis use w…